As a consequence, according to recent ASCO guidelines, SLNB is not recommended for a patient of higher age (≥ 70 years) presenting with cN0, hormone receptor (HR)-positive, and human epidermal growth factor receptor 2 (HER2)-negative BC if the patient will receive adjuvant endocrine treatment [3, 4]. The gene discussed is ERBB2; the disease is breast cancer.